INVO Fertility Reports FY2025 Financial Results: Strategic Moves Signal Transition to Growth Phase
Key Financial Highlights for Fiscal Year 2025
- Total Revenue: \$6.84 million, up 5% year-over-year from \$6.53 million.
- Consolidated Clinic Revenue: \$6.72 million, up 4% from \$6.45 million.
- Aggregate Clinic Revenue (incl. equity method clinics): \$8.02 million, up 4% from \$7.73 million.
- Net Loss from Continuing Operations: \$(5.3) million, a significant improvement from \$(7.7) million in FY2024.
- Adjusted EBITDA: \$(3.2) million, compared to \$(2.2) million in the prior year.
Recent and Strategic Highlights
-
Financing and Balance Sheet Strengthening:
- Secured approximately \$11.5 million in gross proceeds through two financing transactions in December 2025 (\$4 million) and January 2026 (\$7.5 million).
- Proceeds are earmarked to support growth strategies and pay down liabilities.
- All Series C-2 Preferred Stock has been converted or retired, and warrant liabilities eliminated, streamlining the capitalization structure.
- Cash balances have improved, and as of June 2, 2026, the total common shares outstanding is approximately 1.8 million.
-
Expansion into Indiana:
- Acquisition of Family Beginnings, an Indiana-based fertility clinic, closed in February 2026.
- This marks the fourth operational clinic for INVO Fertility in the U.S., expanding its Midwest presence.
- Family Beginnings generated \$1.2 million in revenue and \$0.2 million in net income for the TTM ending September 30, 2025.
-
Employer-Benefit Access Expansion:
- Wisconsin Fertility Institute joined the Progyny network, increasing access to employer-sponsored patients and improving the payor mix.
-
Innovation and Intellectual Property:
- Issued a new patent for a modified INVOcell device, extending IP protection through 2040.
-
Advanced Laboratory Innovation:
- Launched time-lapse incubation technology at the Wisconsin Fertility Institute, providing advanced embryo monitoring to enhance clinical decision-making and patient engagement.
-
Operations Team Strengthening:
- Added key support personnel with deep clinical operations experience to drive clinic performance and growth, and ensure consistent, patient-centered care across all locations.
-
New Organic Growth Initiatives:
- Launched a series of organic growth initiatives at the Atlanta clinic in March 2026, with early signs of meaningful impact.
Strategic Outlook and Management Commentary
Management emphasized that FY2025 was a pivotal year, transitioning INVO Fertility from stabilization to a growth-focused phase. Notably, the strengthened balance sheet, successful financing, and acquisition of Family Beginnings position the company to pursue additional acquisitions, invest in organic growth, and capitalize on favorable market trends in fertility care.
CEO Steve Shum highlighted that the company is now operating from a position of strength, with an improved capital structure, a larger clinic network, and enhanced operational capacity. He also noted the company’s growing credibility as an owner-operator and acquirer in the fertility clinic market, which could drive further M&A activity.
Detailed Financials
-
Operating Expenses:
- Total operating expenses rose to \$14.08 million from \$13.16 million, primarily due to increased cost of services, higher impairment charges on intangibles, and moderate SG&A savings.
- Cost of services: \$4.28 million (up from \$3.65 million).
- Impairment of intangible assets: \$1.40 million (none in prior year).
- SG&A: \$7.69 million (down from \$8.07 million).
-
Other Income (Expense):
- Significant gain on changes in fair value: \$5.17 million (none in prior year).
- Loss from debt extinguishment: \$(2.14) million.
- Loss on issuance of warrants: \$(0.94) million.
- Net other income (expense): \$1.75 million (vs. \$(0.97) million prior year).
-
Net Results:
- Net loss from continuing operations: \$(5.34) million (improved from \$(7.74) million).
- Net loss attributable to common shareholders: \$(25.13) million (vs. \$(9.51) million), reflecting \$16.45 million loss from discontinued operations and \$1.81 million in common stock warrants deemed dividends.
- Net loss per share (basic and diluted): \$(214.64) compared to \$(3,782.65) in FY2024, impacted by share count changes.
- Weighted average common shares outstanding: 117,083 (up from 2,514), reflecting recapitalization and conversions.
-
Adjusted EBITDA:
- \$(3.17) million, up from \$(2.25) million, with reconciliation details provided for investor transparency.
What Investors Need to Know: Potentially Price-Sensitive Information
- Balance Sheet Transformation: The company now has a streamlined capital structure, higher cash balances, and no preferred stock or warrant liability overhang. This dramatically improves optionality for future growth, M&A, and could positively affect share value.
- Acquisition and Organic Growth: The successful integration of Family Beginnings, continued organic growth at the Atlanta clinic, and expansion of third-party payer access position the company for higher revenue and potential margin improvements.
- Innovation & IP: New patent protection for the INVOcell device through 2040 secures a competitive moat and could enhance future licensing or product sale opportunities.
- Share Structure: Shareholders should note the dramatic increase in shares outstanding (now ~1.8 million) due to conversions and recapitalization. This impacts per-share metrics and future dilution risk.
- Discontinued Operations: The company took a substantial loss from discontinued operations in 2025 (\$(16.45) million), which may affect short-term sentiment but positions the ongoing business for better focus and performance.
About INVO Fertility
INVO Fertility is a healthcare services fertility company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics. The company also markets the proprietary INVOcell device, which enables a unique, in-body fertilization and embryo culture process. As of June 2026, INVO operates four clinics in the United States and continues to innovate with a focus on affordability, access, and clinical outcomes.
Contact Information
Company Contact: Steve Shum, CEO | [email protected] | 978-878-9505
Investor Relations: Lytham Partners, LLC | Robert Blum | [email protected] | 602-889-9700
Disclaimer
The above article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, including those detailed in the company’s SEC filings. Actual results may differ materially. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions.
